Intermediate fibrosis staging in hepatitis C: a problem not overcome by optimal samples or pathologists’ expertise
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 5
Abstract
Background and aims. The prediction of intermediate stage of fibrosis in chronic hepatitis C represents a prognostic factor for disease progression. Studies evaluating biopsy performance in intermediate stage considering current patterns of liver samples and pathologists’ variability are scarce. We aimed to evaluate the effect of optimal liver specimens (≥ 20 mm and/or ≥ 11 portal tracts) and pathologists’ expertise on agreement for intermediate stage of fibrosis in chronic hepatitis C. Material and methods. Guided biopsies with large TruCut needle were initially scored by four pathologists with different expertise in liver disease and posteriorly reviewed by a reference hepatopathologist to evaluate fibrosis agreement. Results. Of the 255 biopsies initially selected, 240 met the criteria of an optimal fragment (mean length 24 ± 5 mm; 16 ± 6 portal tracts) and were considered for analysis. The overall agreement among all fibrosis stages was 77% (κ = 0.66); intraobserver and interobserver agreement was, respectively, 97% (k = 0.96) and 73% (κ = 0.60). Excluded samples (< 20 mm and < 11 portal tracts) presented a lower agreement (40%; κ = 0.24). Stratifying fibrosis stages, an interobserver agreement of 42% was found in intermediate stage (F2), ranging from 0 to 56% according to pathologists’ expertise, compared to 97% in mild (F0-F1) and 72% in advanced fibrosis (≥ F3) (p < 0.001). Of the 23% misclassified cases, fibrosis understaging occurred in 82% of specimens, predominantly in F2, even when evaluated by a hepatopathologist. Conclusions. Liver biopsy presents intrinsic limitations to assess intermediate stage of fibrosis not overcome by optimal samples and experienced pathologists’ analysis, and should not be considered the gold standard method to evaluate intermediate fibrosis in chronic hepatitis C.
Authors and Affiliations
Maria C. Chindamo, Vera L. Nunes-Pannain, João M. Araújo-Neto, Henrique S. Moraes-Coelho, Ronir R. Luiz, Cristiane A. Villela-Nogueira, Renata M. Perez
Keywords
Related Articles
- EP ID EP78490
- DOI -
- Views 120
- Downloads 0
Hepatotoxicity from ingestion of wild mushrooms of the genus Amanita section Phalloideae collected in Mexico City: two case reports
We present two cases of acute liver injury resulting from consumption of wild mushrooms. The first case was a male who developed acute hepatitis after ingestion of diverse mushrooms including Amanita species. His clinica...
MEXICAN CONSENSUS ON THE DIAGNOSIS AND MANAGEMENT OF HEPATITIS C INFECTION
Treatment of recurrent hepatitis C post-liver transplantation
Recurrent hepatitis C after liver transplantation is universal. Graft reinfection occurs rapidly, with chronic hepatitis and rapid evolution from end-stage liver disease. Within 5 years until 30% of patients with recurre...
Hepatic Echinococcosis with Thoracic Involvement. Clinical Characteristics of a Prospective Series of Cases
Abstract Introduction. Thoracic involvement (TIHE) is one of the evolutionary complications of hepatic echinococcosis (HE). Aim. The aim of this study was to describe the clinical characteristics and postoperative morbid...
Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe
Background and rationale for the study. Limited studies have aimed to define the cut-offs of XL probe (XL cut-offs) for different stages of liver fibrosis, whereas those of M probe (M cut-offs) may not be applicable to X...